Advantages and Limitations of the Federal Adverse Events Reporting System in Assessing Adverse Event Reporting for Eluxadoline

Overview

Journal Clin Gastroenterol Hepatol

Specialty Gastroenterology

Date 2017 Nov 21

PMID 29155353

Citations 12

Authors

Victor Chedid

Priya Vijayvargiya

Michael Camilleri

Affiliations

Soon will be listed here.

Citing Articles

Investigating the Benefit-Risk Profile of Drugs: From Spontaneous Reporting Systems to Real-World Data for Pharmacovigilance.

Imbrici P, De Bellis M, Liantonio A, De Luca A Methods Mol Biol. 2024; 2834:333-349.

PMID: 39312173 DOI: 10.1007/978-1-0716-4003-6_16.

Adverse drug events associated with linezolid administration: a real-world pharmacovigilance study from 2004 to 2023 using the FAERS database.

Zou F, Cui Z, Lou S, Ou Y, Zhu C, Shu C Front Pharmacol. 2024; 15:1338902.

PMID: 38434706 PMC: 10904462. DOI: 10.3389/fphar.2024.1338902.

A systematic analysis and data mining of opioid-related adverse events submitted to the FAERS database.

Le H, Hong H, Ge W, Francis H, Lyn-Cook B, Hwang Y Exp Biol Med (Maywood). 2023; 248(21):1944-1951.

PMID: 38158803 PMC: 10798186. DOI: 10.1177/15353702231211860.

Metabolic modeling of sex-specific liver tissue suggests mechanism of differences in toxicological responses.

Moore C, Holstege C, Papin J PLoS Comput Biol. 2023; 19(8):e1010927.

PMID: 37603574 PMC: 10470949. DOI: 10.1371/journal.pcbi.1010927.

A retrospective study of adverse drug events in anticoagulant administration with relevance to COVID-19.

Patel P, Gaddis M, Xu X, Riviere J, Kawakami J, Meyer E Heliyon. 2023; 9(3):e13763.

PMID: 36855650 PMC: 9951606. DOI: 10.1016/j.heliyon.2023.e13763.

References

Camilleri M . Peripheral mechanisms in irritable bowel syndrome. N Engl J Med. 2012; 367(17):1626-35. DOI: 10.1056/NEJMra1207068. View

Badalov N, Baradarian R, Iswara K, Li J, Steinberg W, Tenner S . Drug-induced acute pancreatitis: an evidence-based review. Clin Gastroenterol Hepatol. 2007; 5(6):648-61. DOI: 10.1016/j.cgh.2006.11.023. View

Lavo B, Stenstam M, Nielsen A . Loperamide in treatment of irritable bowel syndrome--a double-blind placebo controlled study. Scand J Gastroenterol Suppl. 1987; 130:77-80. DOI: 10.3109/00365528709091003. View

Varga E, Navratilova E, Stropova D, Jambrosic J, Roeske W, Yamamura H . Agonist-specific regulation of the delta-opioid receptor. Life Sci. 2004; 76(6):599-612. DOI: 10.1016/j.lfs.2004.07.020. View

Lembo A, Lacy B, Zuckerman M, Schey R, Dove L, Andrae D . Eluxadoline for Irritable Bowel Syndrome with Diarrhea. N Engl J Med. 2016; 374(3):242-53. DOI: 10.1056/NEJMoa1505180. View

Jordan B, Cvejic S, Devi L . Opioids and their complicated receptor complexes. Neuropsychopharmacology. 2000; 23(4 Suppl):S5-S18. DOI: 10.1016/S0893-133X(00)00143-3. View

Schiller P, Fundytus M, Merovitz L, Weltrowska G, Nguyen T, Lemieux C . The opioid mu agonist/delta antagonist DIPP-NH(2)[Psi] produces a potent analgesic effect, no physical dependence, and less tolerance than morphine in rats. J Med Chem. 1999; 42(18):3520-6. DOI: 10.1021/jm980724+. View

Sobolewska-Wlodarczyk A, Wlodarczyk M, Storr M, Fichna J . Clinical potential of eluxadoline in the treatment of diarrhea-predominant irritable bowel syndrome. Ther Clin Risk Manag. 2016; 12:771-5. PMC: 4874728. DOI: 10.2147/TCRM.S83722. View

Dove L, Lembo A, Randall C, Fogel R, Andrae D, Davenport J . Eluxadoline benefits patients with irritable bowel syndrome with diarrhea in a phase 2 study. Gastroenterology. 2013; 145(2):329-38.e1. DOI: 10.1053/j.gastro.2013.04.006. View

10.

Efskind P, Bernklev T, Vatn M . A double-blind placebo-controlled trial with loperamide in irritable bowel syndrome. Scand J Gastroenterol. 1996; 31(5):463-8. DOI: 10.3109/00365529609006766. View

11.

Gawron A, Bielefeldt K . Risk of Pancreatitis Following Treatment of Irritable Bowel Syndrome With Eluxadoline. Clin Gastroenterol Hepatol. 2017; 16(3):378-384.e2. DOI: 10.1016/j.cgh.2017.08.006. View

12.

Ford A, Lacy B, Talley N . Irritable Bowel Syndrome. N Engl J Med. 2017; 376(26):2566-2578. DOI: 10.1056/NEJMra1607547. View

13.

Hovdenak N . Loperamide treatment of the irritable bowel syndrome. Scand J Gastroenterol Suppl. 1987; 130:81-4. DOI: 10.3109/00365528709091004. View

14.

Camilleri M, Ford A . Irritable Bowel Syndrome: Pathophysiology and Current Therapeutic Approaches. Handb Exp Pharmacol. 2016; 239:75-113. DOI: 10.1007/164_2016_102. View

15.

Afghani E, Lo S, Covington P, Cash B, Pandol S . Sphincter of Oddi Function and Risk Factors for Dysfunction. Front Nutr. 2017; 4:1. PMC: 5276812. DOI: 10.3389/fnut.2017.00001. View

16.

Simren M, Palsson O, Whitehead W . Update on Rome IV Criteria for Colorectal Disorders: Implications for Clinical Practice. Curr Gastroenterol Rep. 2017; 19(4):15. PMC: 5378729. DOI: 10.1007/s11894-017-0554-0. View

17.

Cash B, Lacy B, Schoenfeld P, Dove L, Covington P . Safety of Eluxadoline in Patients with Irritable Bowel Syndrome with Diarrhea. Am J Gastroenterol. 2016; 112(2):365-374. PMC: 5318664. DOI: 10.1038/ajg.2016.542. View

18.

KASICH A . Treatment of diarrhea in irritable colon, including preliminary observations with a new antidiarrheal agent, diphenoxylate hydrochloride (Lomotil). Am J Gastroenterol. 1961; 35:46-9. View